BiotechTube

Iptcaopan 200 mg

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atypical Hemolytic Uremic Syndrome

Conditions

Atypical Hemolytic Uremic Syndrome

Trial Timeline

May 8, 2024 → Jan 3, 2033

NCT ID
NCT05795140

About Iptcaopan 200 mg

Iptcaopan 200 mg is a phase 3 stage product being developed by Novartis for Atypical Hemolytic Uremic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05795140. Target conditions include Atypical Hemolytic Uremic Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05795140Phase 3Recruiting

Competing Products

18 competing products in Atypical Hemolytic Uremic Syndrome

See all competitors
ProductCompanyStageHype Score
CrovalimabChugai PharmaceuticalPhase 3
77
CrovalimabChugai PharmaceuticalPhase 3
77
DuloxetineEli LillyApproved
85
Teriparatide 20 mcgEli LillyPhase 3
77
BaricitinibEli LillyPre-clinical
23
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
IptacopanNovartisPhase 3
77
IptacopanNovartisPhase 3
77
Ropeginterferon Alfa-2BPharmaEssentiaPhase 2
51
CCX168AmgenPhase 2
51
Tazemetostat + Nivolumab + IpilimumabBristol Myers SquibbPhase 1/2
40
CemdisiranAlnylam PharmaceuticalsPhase 2
49
cemdisiran + PlacebosAlnylam PharmaceuticalsPhase 2
49
Axatilimab + AzacitidineIncytePhase 1/2
38
Gemcitabine + PaxalisibPacific BiosciencesPhase 2
44
Apatinib MesylateBrain BiotechPre-clinical
15
azurin-derived cell-penetrating peptide p28Brain BiotechPhase 1
25

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85